These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Biswas S; Sengupta S; Roy Chowdhury S; Jana S; Mandal G; Mandal PK; Saha N; Malhotra V; Gupta A; Kuprash DV; Bhattacharyya A Breast Cancer Res Treat; 2014 Jan; 143(2):265-76. PubMed ID: 24337540 [TBL] [Abstract][Full Text] [Related]
8. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma. Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842 [TBL] [Abstract][Full Text] [Related]
9. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts. Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407 [TBL] [Abstract][Full Text] [Related]
10. Serum CXCL13 as a Novel Biomarker in Oral Squamous Cell Carcinoma. Tojo S; Nakashiro KI; Kuribayashi N; Uchida D Cancer Med; 2024 Sep; 13(18):e70263. PubMed ID: 39344390 [TBL] [Abstract][Full Text] [Related]
12. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Zhang X; Junior CR; Liu M; Li F; D'Silva NJ; Kirkwood KL Oral Oncol; 2013 Feb; 49(2):119-28. PubMed ID: 22989723 [TBL] [Abstract][Full Text] [Related]
13. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. Tohyama R; Kayamori K; Sato K; Hamagaki M; Sakamoto K; Yasuda H; Yamaguchi A J Oral Pathol Med; 2016 May; 45(5):356-64. PubMed ID: 26859422 [TBL] [Abstract][Full Text] [Related]
14. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459 [TBL] [Abstract][Full Text] [Related]
17. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684 [TBL] [Abstract][Full Text] [Related]
18. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. Quan J; Zhou C; Johnson NW; Francis G; Dahlstrom JE; Gao J Pathology; 2012 Apr; 44(3):221-7. PubMed ID: 22406484 [TBL] [Abstract][Full Text] [Related]
19. RelA driven co-expression of CXCL13 and CXCR5 is governed by a multifaceted transcriptional program regulating breast cancer progression. Biswas S; Roy Chowdhury S; Mandal G; Purohit S; Gupta A; Bhattacharyya A Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):502-511. PubMed ID: 30553016 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]